Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

KRRO

+ Watchlist+ Portfolio

Korro Bio, Inc.

Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$12.44
52-Week Range
$5.20 – $17.35
Market Cap
$167.32M
P/E (TTM)
—
EPS (TTM)
-8.89
Dividend Yield
0.00%
Advanced Metrics
Price/Book
1.89
PEG Ratio
—
Return on Equity
-113.26%
Return on Assets
-30.73%
Gross Margin
0.00%
Operating Margin
-5891.49%
Profit Margin
0.00%
Current Ratio
7.30
Debt/Equity
0.47
Total Debt
$41.52M
Free Cash Flow
$-34.05M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$107.28M

Market Snapshot

About

Korro Bio is a biopharmaceutical company pioneering RNA editing therapeutics using proprietary OPERA (Oligonucleotide Promoted Editing of RNA) technology. The company's platform enables precise, programmable editing of RNA to correct disease-causing mutations and modulate protein function. Korro is developing treatments for genetic diseases affecting the liver, central nervous system, and other organs with high unmet medical needs.